{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:18:09Z","timestamp":1790763489942,"version":"4.1.0"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1038\/s41571-022-00649-7","type":"journal-article","created":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T09:03:09Z","timestamp":1656666189000},"page":"573-584","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Immunotherapy approaches for malignant pleural mesothelioma"],"prefix":"10.1038","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7373-1312","authenticated-orcid":false,"given":"Dean A.","family":"Fennell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Dulloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Harber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,1]]},"reference":[{"key":"649_CR1","unstructured":"Cancer Research UK. Mesothelioma Incidence Statistics https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/mesothelioma\/incidence#heading-three (2022)."},{"key":"649_CR2","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1093\/ejcts\/ezv422","volume":"49","author":"DY Kircheva","year":"2016","unstructured":"Kircheva, D. Y. et al. Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma. Eur. J. Cardiothorac. Surg. 49, 1642\u20131647 (2016).","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"649_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jtho.2019.08.2506","volume":"15","author":"AG Nicholson","year":"2020","unstructured":"Nicholson, A. G. et al. EURACAN\/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach. J. Thorac. Oncol. 15, 29\u201349 (2020).","journal-title":"J. Thorac. Oncol."},{"key":"649_CR4","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"397","author":"P Baas","year":"2021","unstructured":"Baas, P. et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 397, 375\u2013386 (2021).","journal-title":"Lancet"},{"key":"649_CR5","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.jtho.2020.01.025","volume":"15","author":"F Galateau Salle","year":"2020","unstructured":"Galateau Salle, F. et al. Comprehensive molecular and pathologic evaluation of transitional mesothelioma assisted by deep learning approach: a multi-institutional study of the international mesothelioma panel from the MESOPATH reference center. J. Thorac. Oncol. 15, 1037\u20131053 (2020).","journal-title":"J. Thorac. Oncol."},{"key":"649_CR6","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","volume":"8","author":"J Hmeljak","year":"2018","unstructured":"Hmeljak, J. et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 8, 1548\u20131565 (2018).","journal-title":"Cancer Discov."},{"key":"649_CR7","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"Bueno, R. et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat. Genet. 48, 407\u2013416 (2016).","journal-title":"Nat. Genet."},{"key":"649_CR8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.20360","volume":"4","author":"Z Zhai","year":"2021","unstructured":"Zhai, Z. et al. Assessment of global trends in the diagnosis of mesothelioma from 1990 to 2017. JAMA Netw. Open 4, e2120360 (2021).","journal-title":"JAMA Netw. Open"},{"key":"649_CR9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1466","author":"EC Nakajima","year":"2021","unstructured":"Nakajima, E. C. et al. FDA approval summary: nivolumab in combination with ipilimumab for the treatment of unresectable malignant pleural mesothelioma. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1466 (2021).","journal-title":"Clin. Cancer Res."},{"key":"649_CR10","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1638211","volume":"8","author":"A Klampatsa","year":"2019","unstructured":"Klampatsa, A. et al. Phenotypic and functional analysis of malignant mesothelioma tumor-infiltrating lymphocytes. Oncoimmunology 8, e1638211 (2019).","journal-title":"Oncoimmunology"},{"key":"649_CR11","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jtho.2016.06.021","volume":"11","author":"LA Lievense","year":"2016","unstructured":"Lievense, L. A. et al. Pleural effusion of patients with malignant mesothelioma induces macrophage-mediated T cell suppression. J. Thorac. Oncol. 11, 1755\u20131764 (2016).","journal-title":"J. Thorac. Oncol."},{"key":"649_CR12","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1261241","volume":"6","author":"E Marcq","year":"2017","unstructured":"Marcq, E. et al. Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma. Oncoimmunology 6, e1261241 (2017).","journal-title":"Oncoimmunology"},{"key":"649_CR13","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1158\/2326-6066.CIR-16-0171","volume":"4","author":"MM Awad","year":"2016","unstructured":"Awad, M. M. et al. Cytotoxic T cells in PD-L1-positive malignant pleural mesotheliomas are counterbalanced by distinct immunosuppressive factors. Cancer Immunol. Res. 4, 1038\u20131048 (2016).","journal-title":"Cancer Immunol. Res."},{"key":"649_CR14","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/j.jtho.2016.06.022","volume":"11","author":"AL Ch\u00e9n\u00e9","year":"2016","unstructured":"Ch\u00e9n\u00e9, A. L. et al. Pleural effusions from patients with mesothelioma induce recruitment of monocytes and their differentiation into M2 macrophages. J. Thorac. Oncol. 11, 1765\u20131773 (2016).","journal-title":"J. Thorac. Oncol."},{"key":"649_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000182","author":"T Blondy","year":"2020","unstructured":"Blondy, T. et al. Involvement of the M-CSF\/IL-34\/CSF-1R pathway in malignant pleural mesothelioma. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2019-000182 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"649_CR16","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1009285","volume":"4","author":"H Ujiie","year":"2015","unstructured":"Ujiie, H. et al. The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: a comprehensive analysis reveals prognostic immune markers. Oncoimmunology 4, e1009285 (2015).","journal-title":"Oncoimmunology"},{"key":"649_CR17","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1093\/annonc\/mdy086","volume":"29","author":"G Pasello","year":"2018","unstructured":"Pasello, G. et al. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time. Ann. Oncol. 29, 1258\u20131265 (2018).","journal-title":"Ann. Oncol."},{"key":"649_CR18","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1173299","volume":"5","author":"C Jackaman","year":"2016","unstructured":"Jackaman, C., Yeoh, T. L., Acuil, M. L., Gardner, J. K. & Nelson, D. J. Murine mesothelioma induces locally-proliferating IL-10+TNF-\u03b1+CD206-CX3CR1+ M3 macrophages that can be selectively depleted by chemotherapy or immunotherapy. Oncoimmunology 5, e1173299 (2016).","journal-title":"Oncoimmunology"},{"key":"649_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001601","author":"A Alay","year":"2021","unstructured":"Alay, A. et al. Integrative transcriptome analysis of malignant pleural mesothelioma reveals a clinically relevant immune-based classification. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2020-001601 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"649_CR20","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jtho.2017.09.1968","volume":"13","author":"NS Patil","year":"2018","unstructured":"Patil, N. S. et al. Molecular and histopathological characterization of the tumor immune microenvironment in advanced stage of malignant pleural mesothelioma. J. Thorac. Oncol. 13, 124\u2013133 (2018).","journal-title":"J. Thorac. Oncol."},{"key":"649_CR21","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/bjc.2017.269","volume":"117","author":"SJ Chee","year":"2017","unstructured":"Chee, S. J. et al. Evaluating the effect of immune cells on the outcome of patients with mesothelioma. Br. J. Cancer 117, 1341\u20131348 (2017).","journal-title":"Br. J. Cancer"},{"key":"649_CR22","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.jtho.2017.02.013","volume":"12","author":"B Thapa","year":"2017","unstructured":"Thapa, B. et al. The immune microenvironment, genome-wide copy number aberrations, and survival in mesothelioma. J. Thorac. Oncol. 12, 850\u2013859 (2017).","journal-title":"J. Thorac. Oncol."},{"key":"649_CR23","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1038\/mt.2010.159","volume":"18","author":"ZG Fridlender","year":"2010","unstructured":"Fridlender, Z. G. et al. Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms. Mol. Ther. 18, 1947\u20131959 (2010).","journal-title":"Mol. Ther."},{"key":"649_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.103160","author":"F Dammeijer","year":"2020","unstructured":"Dammeijer, F. et al. Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical response. EBioMedicine https:\/\/doi.org\/10.1016\/j.ebiom.2020.103160 (2020).","journal-title":"EBioMedicine"},{"key":"649_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21798-w","volume":"12","author":"M Zhang","year":"2021","unstructured":"Zhang, M. et al. Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment. Nat. Commun. 12, 1751 (2021).","journal-title":"Nat. Commun."},{"key":"649_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09307-6","volume":"10","author":"Y Blum","year":"2019","unstructured":"Blum, Y. et al. Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications. Nat. Commun. 10, 1333 (2019).","journal-title":"Nat. Commun."},{"issue":"Suppl. A","key":"649_CR27","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/0305-7372(89)90036-4","volume":"16","author":"N Thatcher","year":"1989","unstructured":"Thatcher, N. et al. Interleukin-2 in malignant pleural mesothelioma (and adenocarcinoma of the lung). The use of intrapleural and continuous intravenous infusions: preliminary results. Cancer Treat. Rev. 16 (Suppl. A), 161\u2013162 (1989).","journal-title":"Cancer Treat. Rev."},{"key":"649_CR28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0169-5002(00)00157-4","volume":"31","author":"CW Mulatero","year":"2001","unstructured":"Mulatero, C. W. et al. A phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesothelioma. Lung Cancer 31, 67\u201372 (2001).","journal-title":"Lung Cancer"},{"key":"649_CR29","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/icb.1997.55","volume":"75","author":"CC Leong","year":"1997","unstructured":"Leong, C. C., Marley, J. V., Loh, S., Robinson, B. W. & Garlepp, M. J. The induction of immune responses to murine malignant mesothelioma by IL-2 gene transfer. Immunol. Cell Biol. 75, 356\u2013359 (1997).","journal-title":"Immunol. Cell Biol."},{"key":"649_CR30","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1002\/(SICI)1097-0142(19981115)83:10<2099::AID-CNCR8>3.0.CO;2-3","volume":"83","author":"P Astoul","year":"1998","unstructured":"Astoul, P., Picat-Joossen, D., Viallat, J. R. & Boutin, C. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a phase II study. Cancer 83, 2099\u20132104 (1998).","journal-title":"Cancer"},{"key":"649_CR31","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","volume":"14","author":"L Calabro","year":"2013","unstructured":"Calabro, L. et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 14, 1104\u20131111 (2013).","journal-title":"Lancet Oncol."},{"key":"649_CR32","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","volume":"18","author":"M Maio","year":"2017","unstructured":"Maio, M. et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 18, 1261\u20131273 (2017).","journal-title":"Lancet Oncol."},{"key":"649_CR33","doi-asserted-by":"publisher","first-page":"7898","DOI":"10.4049\/jimmunol.0901060","volume":"183","author":"AJ Currie","year":"2009","unstructured":"Currie, A. J. et al. Dual control of antitumor CD8 T cells through the programmed death-1\/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulation. J. Immunol. 183, 7898\u20137908 (2009).","journal-title":"J. Immunol."},{"key":"649_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.humpath.2016.01.010","volume":"52","author":"C Combaz-Lair","year":"2016","unstructured":"Combaz-Lair, C. et al. Immune biomarkers PD-1\/PD-L1 and TLR3 in malignant pleural mesotheliomas. Hum. Pathol. 52, 9\u201318 (2016).","journal-title":"Hum. Pathol."},{"key":"649_CR35","doi-asserted-by":"publisher","first-page":"e564","DOI":"10.1016\/j.cllc.2019.04.010","volume":"20","author":"S Brosseau","year":"2019","unstructured":"Brosseau, S. et al. Shorter survival in malignant pleural mesothelioma patients with high PD-L1 expression associated with sarcomatoid or biphasic histology subtype: a series of 214 cases from the bio-MAPS cohort. Clin. Lung Cancer 20, e564\u2013e575 (2019).","journal-title":"Clin. Lung Cancer"},{"key":"649_CR36","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/pin.13028","volume":"70","author":"E Matsumura","year":"2020","unstructured":"Matsumura, E. et al. Expression status of PD-L1 and B7-H3 in mesothelioma. Pathol. Int. 70, 999\u20131008 (2020).","journal-title":"Pathol. Int."},{"key":"649_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121071","volume":"10","author":"S Cedres","year":"2015","unstructured":"Cedres, S. et al. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). PLoS One 10, e0121071 (2015).","journal-title":"PLoS One"},{"key":"649_CR38","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","volume":"9","author":"AS Mansfield","year":"2014","unstructured":"Mansfield, A. S. et al. B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J. Thorac. Oncol. 9, 1036\u20131040 (2014).","journal-title":"J. Thorac. Oncol."},{"key":"649_CR39","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.ejso.2017.05.009","volume":"43","author":"S Valmary-Degano","year":"2017","unstructured":"Valmary-Degano, S. et al. Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: a RENAPE study. Eur. J. Surg. Oncol. 43, 1915\u20131923 (2017).","journal-title":"Eur. J. Surg. Oncol."},{"key":"649_CR40","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.pathol.2018.05.002","volume":"50","author":"F Forest","year":"2018","unstructured":"Forest, F. et al. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications. Pathology 50, 635\u2013641 (2018).","journal-title":"Pathology"},{"key":"649_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.humpath.2017.04.032","volume":"71","author":"S Inaguma","year":"2018","unstructured":"Inaguma, S. et al. Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma. Hum. Pathol. 71, 1\u20137 (2018).","journal-title":"Hum. Pathol."},{"key":"649_CR42","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/ajco.12788","volume":"14","author":"BH Nguyen","year":"2018","unstructured":"Nguyen, B. H., Montgomery, R., Fadia, M., Wang, J. & Ali, S. PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma. Asia Pac. J. Clin. Oncol. 14, 69\u201373 (2018).","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"649_CR43","doi-asserted-by":"crossref","first-page":"175883592096236","DOI":"10.1177\/1758835920962362","volume":"12","author":"L Jin","year":"2020","unstructured":"Jin, L. et al. PD-L1 and prognosis in patients with malignant pleural mesothelioma: a meta-analysis and bioinformatics study. Ther. Adv. Med. Oncol. 12, 1758835920962362 (2020).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"649_CR44","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.21037\/tlcr-20-1114","volume":"10","author":"L Brcic","year":"2021","unstructured":"Brcic, L. et al. Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study. Transl. Lung Cancer Res. 10, 1594\u20131607 (2021).","journal-title":"Transl. Lung Cancer Res."},{"key":"649_CR45","doi-asserted-by":"publisher","first-page":"20769","DOI":"10.18632\/oncotarget.25100","volume":"9","author":"T Watanabe","year":"2018","unstructured":"Watanabe, T. et al. Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma. Oncotarget 9, 20769\u201320780 (2018).","journal-title":"Oncotarget"},{"key":"649_CR46","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.humpath.2019.02.001","volume":"87","author":"DB Chapel","year":"2019","unstructured":"Chapel, D. B. et al. Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays. Hum. Pathol. 87, 11\u201317 (2019).","journal-title":"Hum. Pathol."},{"key":"649_CR47","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","volume":"18","author":"EW Alley","year":"2017","unstructured":"Alley, E. W. et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol. 18, 623\u2013630 (2017).","journal-title":"Lancet Oncol."},{"key":"649_CR48","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","volume":"13","author":"J Quispel-Janssen","year":"2018","unstructured":"Quispel-Janssen, J. et al. Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma. J. Thorac. Oncol. 13, 1569\u20131576 (2018).","journal-title":"J. Thorac. Oncol."},{"key":"649_CR49","doi-asserted-by":"publisher","first-page":"5485","DOI":"10.1158\/1078-0432.CCR-19-0103","volume":"25","author":"M Okada","year":"2019","unstructured":"Okada, M. et al. Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase II study in malignant pleural mesothelioma (MERIT). Clin. Cancer Res. 25, 5485\u20135492 (2019).","journal-title":"Clin. Cancer Res."},{"key":"649_CR50","first-page":"100135","volume":"2","author":"N Fujimoto","year":"2021","unstructured":"Fujimoto, N. et al. Clinical efficacy and safety of nivolumab in Japanese patients with malignant pleural mesothelioma: 3-year results of the MERIT study. JTO Clin. Res. Rep. 2, 100135 (2021).","journal-title":"JTO Clin. Res. Rep."},{"key":"649_CR51","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1001\/jamaoncol.2018.5428","volume":"5","author":"R Hassan","year":"2019","unstructured":"Hassan, R. et al. Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: phase 1b results from the JAVELIN solid tumor trial. JAMA Oncol. 5, 351\u2013357 (2019).","journal-title":"JAMA Oncol."},{"key":"649_CR52","doi-asserted-by":"publisher","first-page":"783","DOI":"10.12659\/AJCR.909584","volume":"19","author":"RG Jones","year":"2018","unstructured":"Jones, R. G. et al. Nivolumab immunotherapy in malignant mesothelioma: a case report highlighting a new opportunity for exceptional outcomes. Am. J. Case Rep. 19, 783\u2013789 (2018).","journal-title":"Am. J. Case Rep."},{"key":"649_CR53","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-237721","author":"T Tanaka","year":"2020","unstructured":"Tanaka, T., Miyamoto, Y., Sakai, A. & Fujimoto, N. Nivolumab for malignant peritoneal mesothelioma. BMJ Case Rep. https:\/\/doi.org\/10.1136\/bcr-2020-237721 (2020).","journal-title":"BMJ Case Rep."},{"key":"649_CR54","unstructured":"Pharmaceuticals and Medical Devices Agency. Review report https:\/\/www.pmda.go.jp\/files\/000241165.pdf (2020)."},{"key":"649_CR55","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1016\/j.annonc.2020.09.009","volume":"31","author":"S Popat","year":"2020","unstructured":"Popat, S. et al. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. Ann. Oncol. 31, 1734\u20131745 (2020).","journal-title":"Ann. Oncol."},{"key":"649_CR56","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/S2213-2600(20)30362-3","volume":"9","author":"CJ de Gooijer","year":"2021","unstructured":"de Gooijer, C. J. et al. Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial. Lancet Respir. Med. 9, 585\u2013592 (2021).","journal-title":"Lancet Respir. Med."},{"key":"649_CR57","first-page":"850","volume":"39","author":"DA Fennell","year":"2021","unstructured":"Fennell, D. A. et al. A randomized phase II trial of oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma. J. Clin. Oncol. 39, 8507 (2021).","journal-title":"J. Clin. Oncol."},{"key":"649_CR58","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/S1470-2045(21)00471-X","volume":"22","author":"D Fennell","year":"2021","unstructured":"Fennell, D. et al. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind randomised phase III trial. Lancet Oncol. 22, 1530\u20131540 (2021).","journal-title":"Lancet Oncol."},{"key":"649_CR59","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMra1912719","volume":"385","author":"SM Janes","year":"2021","unstructured":"Janes, S. M., Alrifai, D. & Fennell, D. A. Perspectives on the treatment of malignant pleural mesothelioma. N. Engl. J. Med. 385, 1207\u20131218 (2021).","journal-title":"N. Engl. J. Med."},{"key":"649_CR60","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-038892","volume":"10","author":"E Lim","year":"2020","unstructured":"Lim, E. et al. Mesothelioma and Radical Surgery 2 (MARS 2): protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesothelioma. BMJ Open 10, e038892 (2020).","journal-title":"BMJ Open"},{"key":"649_CR61","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","volume":"398","author":"E Felip","year":"2021","unstructured":"Felip, E. et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet 398, 1344\u20131357 (2021).","journal-title":"Lancet"},{"key":"649_CR62","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378, 1277\u20131290 (2018).","journal-title":"N. Engl. J. Med."},{"key":"649_CR63","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23\u201334 (2015).","journal-title":"N. Engl. J. Med."},{"key":"649_CR64","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S2213-2600(18)30151-6","volume":"6","author":"L Calabro","year":"2018","unstructured":"Calabro, L. et al. Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study. Lancet Respir. Med. 6, 451\u2013460 (2018).","journal-title":"Lancet Respir. Med."},{"key":"649_CR65","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/S2213-2600(21)00043-6","volume":"9","author":"L Calabro","year":"2021","unstructured":"Calabro, L. et al. Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study. Lancet Respir. Med. 9, 969\u2013976 (2021).","journal-title":"Lancet Respir. Med."},{"key":"649_CR66","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","volume":"7","author":"MJ Disselhorst","year":"2019","unstructured":"Disselhorst, M. J. et al. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Lancet Respir. Med. 7, 260\u2013270 (2019).","journal-title":"Lancet Respir. Med."},{"key":"649_CR67","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","volume":"20","author":"A Scherpereel","year":"2019","unstructured":"Scherpereel, A. et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol. 20, 239\u2013253 (2019).","journal-title":"Lancet Oncol."},{"key":"649_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.01.074","author":"S Peters","year":"2022","unstructured":"Peters, S. et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann. Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2022.01.074 (2022).","journal-title":"Ann. Oncol."},{"key":"649_CR69","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang, N. J. et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21, 2636\u20132644 (2003).","journal-title":"J. Clin. Oncol."},{"key":"649_CR70","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1158\/1078-0432.CCR-13-2429","volume":"20","author":"A de Reynies","year":"2014","unstructured":"de Reynies, A. et al. Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition. Clin. Cancer Res. 20, 1323\u20131334 (2014).","journal-title":"Clin. Cancer Res."},{"key":"649_CR71","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1200\/EDBK_200643","volume":"38","author":"E Borcoman","year":"2018","unstructured":"Borcoman, E., Nandikolla, A., Long, G., Goel, S. & Tourneau, C. L. Patterns of response and progression to immunotherapy. Am. Soc. Clin. Oncol. Educ. Book 38, 169\u2013178 (2018).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"649_CR72","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jtho.2017.09.001","volume":"13","author":"MB Barnet","year":"2018","unstructured":"Barnet, M. B., Zielinski, R. R., Warby, A., Lewis, C. R. & Kao, S. Pseudoprogression associated with clinical deterioration and worsening quality of life in malignant pleural mesothelioma. J. Thorac. Oncol. 13, e1\u2013e2 (2018).","journal-title":"J. Thorac. Oncol."},{"key":"649_CR73","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","volume":"387","author":"G Zalcman","year":"2016","unstructured":"Zalcman, G. et al. Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma avastin cisplatin pemetrexed study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 387, 1405\u20131414 (2016).","journal-title":"Lancet"},{"key":"649_CR74","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi, L. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378, 2078\u20132092 (2018).","journal-title":"N. Engl. J. Med."},{"key":"649_CR75","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","volume":"379","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares, L. et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N. Engl. J. Med. 379, 2040\u20132051 (2018).","journal-title":"N. Engl. J. Med."},{"key":"649_CR76","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn, L. et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N. Engl. J. Med. 379, 2220\u20132229 (2018).","journal-title":"N. Engl. J. Med."},{"key":"649_CR77","doi-asserted-by":"publisher","first-page":"4905","DOI":"10.4049\/jimmunol.170.10.4905","volume":"170","author":"AK Nowak","year":"2003","unstructured":"Nowak, A. K. et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J. Immunol. 170, 4905\u20134913 (2003).","journal-title":"J. Immunol."},{"key":"649_CR78","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/S1470-2045(20)30462-9","volume":"21","author":"AK Nowak","year":"2020","unstructured":"Nowak, A. K. et al. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. Lancet Oncol. 21, 1213\u20131223 (2020).","journal-title":"Lancet Oncol."},{"key":"649_CR79","doi-asserted-by":"publisher","first-page":"9003","DOI":"10.1200\/JCO.2020.38.15_suppl.9003","volume":"38","author":"PM Forde","year":"2020","unstructured":"Forde, P. M. et al. PrE0505: phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed for the first-line treatment of unresectable malignant pleural mesothelioma (MPM) \u2014 a PrECOG LLC study. J. Clin. Oncol. 38, 9003 (2020).","journal-title":"J. Clin. Oncol."},{"key":"649_CR80","doi-asserted-by":"publisher","first-page":"TPS8586","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS8586","volume":"39","author":"PM Forde","year":"2021","unstructured":"Forde, P. M. et al. DREAM3R: durvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma \u2014 a phase 3 randomized trial. J. Clin. Oncol. 39, TPS8586 (2021).","journal-title":"J. Clin. Oncol."},{"key":"649_CR81","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","volume":"22","author":"L Paz-Ares","year":"2021","unstructured":"Paz-Ares, L. et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 22, 198\u2013211 (2021).","journal-title":"Lancet Oncol."},{"key":"649_CR82","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823\u20131833 (2016).","journal-title":"N. Engl. J. Med."},{"key":"649_CR83","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S2213-2600(20)30515-4","volume":"9","author":"TA Yap","year":"2021","unstructured":"Yap, T. A. et al. Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study. Lancet Respir. Med. 9, 613\u2013621 (2021).","journal-title":"Lancet Respir. Med."},{"key":"649_CR84","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jtho.2021.07.029","volume":"17","author":"P Baas","year":"2022","unstructured":"Baas, P. Nivolumab plus ipilimumab should be the standard of care for first-line unresectable epithelioid mesothelioma. J. Thorac. Oncol. 17, 30\u201333 (2022).","journal-title":"J. Thorac. Oncol."},{"key":"649_CR85","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124\u2013128 (2015).","journal-title":"Science"},{"key":"649_CR86","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jtho.2018.10.001","volume":"14","author":"AS Mansfield","year":"2019","unstructured":"Mansfield, A. S. et al. Neoantigenic potential of complex chromosomal rearrangements in mesothelioma. J. Thorac. Oncol. 14, 276\u2013287 (2019).","journal-title":"J. Thorac. Oncol."},{"key":"649_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.10.022","author":"F Kosari","year":"2021","unstructured":"Kosari, F. et al. Tumor junction burden and antigen presentation as predictors of survival in mesothelioma treated with immune checkpoint inhibitors. J. Thorac. Oncol. https:\/\/doi.org\/10.1016\/j.jtho.2021.10.022 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"649_CR88","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25894-9","volume":"12","author":"G Han","year":"2021","unstructured":"Han, G. et al. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nat. Commun. 12, 5606 (2021).","journal-title":"Nat. Commun."},{"key":"649_CR89","doi-asserted-by":"publisher","first-page":"8558","DOI":"10.1200\/JCO.2021.39.15_suppl.8558","volume":"39","author":"DA Fennell","year":"2021","unstructured":"Fennell, D. A. et al. A phase II trial of abemaciclib in patients with p16ink4a negative, relapsed mesothelioma. J. Clin. Oncol. 39, 8558 (2021).","journal-title":"J. Clin. Oncol."},{"key":"649_CR90","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nature23465","volume":"548","author":"S Goel","year":"2017","unstructured":"Goel, S. et al. CDK4\/6 inhibition triggers anti-tumour immunity. Nature 548, 471\u2013475 (2017).","journal-title":"Nature"},{"key":"649_CR91","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0631-0","volume":"11","author":"M Ladanyi","year":"2019","unstructured":"Ladanyi, M., Sanchez Vega, F. & Zauderer, M. Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma. Genome Med. 11, 18 (2019).","journal-title":"Genome Med."},{"key":"649_CR92","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1038\/s41591-021-01541-0","volume":"27","author":"PM Forde","year":"2021","unstructured":"Forde, P. M. et al. Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. Nat. Med. 27, 1910\u20131920 (2021).","journal-title":"Nat. Med."},{"key":"649_CR93","doi-asserted-by":"publisher","first-page":"9503","DOI":"10.1200\/JCO.2020.38.15_suppl.9503","volume":"38","author":"D Rodriguez-Abreu","year":"2020","unstructured":"Rodriguez-Abreu, D. et al. Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE). J. Clin. Oncol. 38, 9503 (2020).","journal-title":"J. Clin. Oncol."},{"key":"649_CR94","doi-asserted-by":"publisher","first-page":"103040","DOI":"10.1016\/j.ebiom.2020.103040","volume":"62","author":"JM Mankor","year":"2020","unstructured":"Mankor, J. M. et al. Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials. EBioMedicine 62, 103040 (2020).","journal-title":"EBioMedicine"},{"key":"649_CR95","doi-asserted-by":"publisher","first-page":"584423","DOI":"10.3389\/fimmu.2020.584423","volume":"11","author":"N Principe","year":"2020","unstructured":"Principe, N. et al. Tumor infiltrating effector memory antigen-specific CD8+ T cells predict response to immune checkpoint therapy. Front. Immunol. 11, 584423 (2020).","journal-title":"Front. Immunol."},{"key":"649_CR96","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1158\/1078-0432.CCR-17-2257","volume":"24","author":"J Edwards","year":"2018","unstructured":"Edwards, J. et al. CD103+ tumor-resident CD8+ T cells are associated with improved survival in immunotherapy-naive melanoma patients and expand significantly during anti-PD-1 treatment. Clin. Cancer Res. 24, 3036\u20133045 (2018).","journal-title":"Clin. Cancer Res."},{"key":"649_CR97","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002231","author":"R Banchereau","year":"2021","unstructured":"Banchereau, R. et al. Intratumoral CD103+CD8+ T cells predict response to PD-L1 blockade. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2020-002231 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"649_CR98","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink, B. A. et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577, 549\u2013555 (2020).","journal-title":"Nature"},{"key":"649_CR99","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","volume":"577","author":"F Petitprez","year":"2020","unstructured":"Petitprez, F. et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature 577, 556\u2013560 (2020).","journal-title":"Nature"},{"key":"649_CR100","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0331","author":"K Raghav","year":"2021","unstructured":"Raghav, K. et al. Efficacy, safety, and biomarker analysis of combined PD-L1 (Atezolizumab) and VEGF (bevacizumab) blockade in advanced malignant peritoneal mesothelioma. Cancer Discov. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0331 (2021).","journal-title":"Cancer Discov."},{"key":"649_CR101","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.cell.2015.09.001","volume":"163","author":"A Serrels","year":"2015","unstructured":"Serrels, A. et al. Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity. Cell 163, 160\u2013173 (2015).","journal-title":"Cell"},{"key":"649_CR102","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1016\/j.jtho.2019.06.020","volume":"14","author":"MS Tsao","year":"2019","unstructured":"Tsao, M. S. et al. Pathologic considerations and standardization in mesothelioma clinical trials. J. Thorac. Oncol. 14, 1704\u20131717 (2019).","journal-title":"J. Thorac. Oncol."},{"key":"649_CR103","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12102757","author":"W Song","year":"2020","unstructured":"Song, W. et al. AXL inactivation inhibits mesothelioma growth and migration via regulation of p53 expression. Cancers https:\/\/doi.org\/10.3390\/cancers12102757 (2020).","journal-title":"Cancers"},{"key":"649_CR104","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/onc.2010.555","volume":"30","author":"WB Ou","year":"2011","unstructured":"Ou, W. B. et al. AXL regulates mesothelioma proliferation and invasiveness. Oncogene 30, 1643\u20131652 (2011).","journal-title":"Oncogene"},{"key":"649_CR105","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1016\/j.celrep.2018.11.054","volume":"25","author":"L Ding","year":"2018","unstructured":"Ding, L. et al. PARP inhibition elicits STING-dependent antitumor immunity in Brca1-deficient ovarian cancer. Cell Rep. 25, 2972\u20132980.e5 (2018).","journal-title":"Cell Rep."},{"key":"649_CR106","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1158\/0008-5472.CAN-18-1003","volume":"79","author":"J Shen","year":"2019","unstructured":"Shen, J. et al. PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness. Cancer Res. 79, 311\u2013319 (2019).","journal-title":"Cancer Res."},{"key":"649_CR107","doi-asserted-by":"publisher","first-page":"7483","DOI":"10.1158\/1078-0432.CCR-17-2169","volume":"23","author":"MG Zauderer","year":"2017","unstructured":"Zauderer, M. G. et al. A randomized phase II trial of adjuvant galinpepimut-S, WT-1 analogue peptide vaccine, after multimodality therapy for patients with malignant pleural mesothelioma. Clin. Cancer Res. 23, 7483\u20137489 (2017).","journal-title":"Clin. Cancer Res."},{"key":"649_CR108","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1007\/s00262-010-0871-8","volume":"59","author":"LM Krug","year":"2010","unstructured":"Krug, L. M. et al. WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. Cancer Immunol. Immunother. 59, 1467\u20131479 (2010).","journal-title":"Cancer Immunol. Immunother."},{"key":"649_CR109","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1164\/rccm.200312-1683OC","volume":"169","author":"F Ebstein","year":"2004","unstructured":"Ebstein, F. et al. Cytotoxic T cell responses against mesothelioma by apoptotic cell-pulsed dendritic cells. Am. J. Respir. Crit. Care Med. 169, 1322\u20131330 (2004).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"649_CR110","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1164\/rccm.200501-057OC","volume":"171","author":"JP Hegmans","year":"2005","unstructured":"Hegmans, J. P., Hemmes, A., Aerts, J. G., Hoogsteden, H. C. & Lambrecht, B. N. Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells. Am. J. Respir. Crit. Care Med. 171, 1168\u20131177 (2005).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"649_CR111","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1164\/rccm.200909-1465OC","volume":"181","author":"JP Hegmans","year":"2010","unstructured":"Hegmans, J. P. et al. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. Am. J. Respir. Crit. Care Med. 181, 1383\u20131390 (2010).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"649_CR112","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9050525","author":"DW Dumoulin","year":"2021","unstructured":"Dumoulin, D. W., Cornelissen, R., Bezemer, K., Baart, S. J. & Aerts, J. Long-term follow-up of mesothelioma patients treated with dendritic cell therapy in three phase I\/II trials. Vaccines https:\/\/doi.org\/10.3390\/vaccines9050525 (2021).","journal-title":"Vaccines"},{"key":"649_CR113","doi-asserted-by":"publisher","first-page":"280","DOI":"10.21037\/tlcr.2019.05.05","volume":"8","author":"RA Belderbos","year":"2019","unstructured":"Belderbos, R. A. et al. A multicenter, randomized, phase II\/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial. Transl. Lung Cancer Res. 8, 280\u2013285 (2019).","journal-title":"Transl. Lung Cancer Res."},{"key":"649_CR114","first-page":"6201","volume":"61","author":"M Odaka","year":"2001","unstructured":"Odaka, M. et al. Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-beta gene therapy is attributable to induction of systemic immunity. Cancer Res. 61, 6201\u20136212 (2001).","journal-title":"Cancer Res."},{"key":"649_CR115","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1006\/mthe.2002.0656","volume":"6","author":"M Odaka","year":"2002","unstructured":"Odaka, M. et al. Analysis of the immunologic response generated by Ad.IFN-beta during successful intraperitoneal tumor gene therapy. Mol. Ther. 6, 210\u2013218 (2002).","journal-title":"Mol. Ther."},{"key":"649_CR116","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1164\/rccm.201103-0554CR","volume":"184","author":"DH Sterman","year":"2011","unstructured":"Sterman, D. H. et al. A trial of intrapleural adenoviral-mediated Interferon-alpha2b gene transfer for malignant pleural mesothelioma. Am. J. Respir. Crit. Care Med. 184, 1395\u20131399 (2011).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"649_CR117","first-page":"7845","volume":"63","author":"P DeLong","year":"2003","unstructured":"DeLong, P. et al. Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy. Cancer Res. 63, 7845\u20137852 (2003).","journal-title":"Cancer Res."},{"key":"649_CR118","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.1158\/1078-0432.CCR-15-2133","volume":"22","author":"DH Sterman","year":"2016","unstructured":"Sterman, D. H. et al. Pilot and feasibility trial evaluating immuno-gene therapy of malignant mesothelioma using intrapleural delivery of adenovirus-IFNalpha combined with chemotherapy. Clin. Cancer Res. 22, 3791\u20133800 (2016).","journal-title":"Clin. Cancer Res."},{"key":"649_CR119","doi-asserted-by":"publisher","first-page":"4456","DOI":"10.1158\/1078-0432.CCR-07-0403","volume":"13","author":"DH Sterman","year":"2007","unstructured":"Sterman, D. H. et al. A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clin. Cancer Res. 13, 4456\u20134466 (2007).","journal-title":"Clin. Cancer Res."},{"key":"649_CR120","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/mt.2009.309","volume":"18","author":"DH Sterman","year":"2010","unstructured":"Sterman, D. H. et al. A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions. Mol. Ther. 18, 852\u2013860 (2010).","journal-title":"Mol. Ther."},{"key":"649_CR121","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1158\/1078-0432.CCR-11-0351","volume":"17","author":"EK Moon","year":"2011","unstructured":"Moon, E. K. et al. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin. Cancer Res. 17, 4719\u20134730 (2011).","journal-title":"Clin. Cancer Res."},{"key":"649_CR122","doi-asserted-by":"publisher","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","volume":"6","author":"PS Adusumilli","year":"2014","unstructured":"Adusumilli, P. S. et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci. Transl. Med. 6, 261ra151 (2014).","journal-title":"Sci. Transl. Med."},{"key":"649_CR123","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1172\/JCI83092","volume":"126","author":"L Cherkassky","year":"2016","unstructured":"Cherkassky, L. et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J. Clin. Invest. 126, 3130\u20133144 (2016).","journal-title":"J. Clin. Invest."},{"key":"649_CR124","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","volume":"11","author":"PS Adusumilli","year":"2021","unstructured":"Adusumilli, P. S. et al. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab. Cancer Discov. 11, 2748\u20132763 (2021).","journal-title":"Cancer Discov."},{"key":"649_CR125","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.annonc.2020.10.474","volume":"32","author":"S Hiltbrunner","year":"2021","unstructured":"Hiltbrunner, S. et al. Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, a phase I clinical trial. Ann. Oncol. 32, 120\u2013121 (2021).","journal-title":"Ann. Oncol."},{"key":"649_CR126","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd8836","author":"A Hyrenius-Wittsten","year":"2021","unstructured":"Hyrenius-Wittsten, A. et al. SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.abd8836 (2021).","journal-title":"Sci. Transl. Med."},{"key":"649_CR127","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1363137","volume":"6","author":"T Thayaparan","year":"2017","unstructured":"Thayaparan, T. et al. CAR T-cell immunotherapy of MET-expressing malignant mesothelioma. Oncoimmunology 6, e1363137 (2017).","journal-title":"Oncoimmunology"}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-022-00649-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-022-00649-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-022-00649-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T13:13:18Z","timestamp":1661173998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-022-00649-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,1]]},"references-count":127,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["649"],"URL":"https:\/\/doi.org\/10.1038\/s41571-022-00649-7","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,1]]},"assertion":[{"value":"18 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.A.F. has received grants from Astex Therapeutics, Bayer, Boehringer Ingelheim and MSD; personal fees from Aldeyra, Inventiva, Paredox and Roche; and non-financial support (involving the provision of study drugs) from Bergen Bio, BMS, Clovis Oncology, Eli Lilly, Pierre Fabre and Roche. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}